BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van Kessel SP, El Aidy S. Contributions of Gut Bacteria and Diet to Drug Pharmacokinetics in the Treatment of Parkinson's Disease. Front Neurol 2019;10:1087. [PMID: 31681153 DOI: 10.3389/fneur.2019.01087] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 van Kessel SP, Auvinen P, Scheperjans F, El Aidy S. Gut bacterial tyrosine decarboxylase associates with clinical variables in a longitudinal cohort study of Parkinsons disease. NPJ Parkinsons Dis 2021;7:115. [PMID: 34911958 DOI: 10.1038/s41531-021-00260-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
2 Bhidayasiri R, Phuenpathom W, Tan AH, Leta V, Phumphid S, Chaudhuri KR, Pal PK. Management of dysphagia and gastroparesis in Parkinson’s disease in real-world clinical practice – Balancing pharmacological and non-pharmacological approaches. Front Aging Neurosci 2022;14:979826. [DOI: 10.3389/fnagi.2022.979826] [Reference Citation Analysis]
3 Safarpour D, Sharzehi K, Pfeiffer RF. Gastrointestinal Dysfunction in Parkinson’s Disease. Drugs. [DOI: 10.1007/s40265-021-01664-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Alfonsetti M, Castelli V, d'Angelo M. Are We What We Eat? Impact of Diet on the Gut-Brain Axis in Parkinson's Disease. Nutrients 2022;14:380. [PMID: 35057561 DOI: 10.3390/nu14020380] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Mukhtar I, Anwar H, Mirza OA, Ali Q, Ijaz MU, Hume M, Prabhala BK, Iftikhar A, Hussain G, Sohail MU, Khan KUR. Sulpiride Serves, a Substrate for the Gut Microbiome. Dose Response 2021;19:1559325820987943. [PMID: 33628152 DOI: 10.1177/1559325820987943] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Beckers M, Bloem BR, Verbeek MM. Mechanisms of peripheral levodopa resistance in Parkinson's disease. NPJ Parkinsons Dis 2022;8:56. [PMID: 35546556 DOI: 10.1038/s41531-022-00321-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Dănău A, Dumitrescu L, Lefter A, Tulbă D, Popescu BO. Small Intestinal Bacterial Overgrowth as Potential Therapeutic Target in Parkinson's Disease. Int J Mol Sci 2021;22:11663. [PMID: 34769091 DOI: 10.3390/ijms222111663] [Reference Citation Analysis]
8 Lopes M, Coimbra MA, Costa MDC, Ramos F. Food supplement vitamins, minerals, amino-acids, fatty acids, phenolic and alkaloid-based substances: An overview of their interaction with drugs. Crit Rev Food Sci Nutr 2021;:1-35. [PMID: 34792411 DOI: 10.1080/10408398.2021.1997909] [Reference Citation Analysis]
9 Vijiaratnam N, Foltynie T. Therapeutic Strategies to Treat or Prevent Off Episodes in Adults with Parkinson's Disease. Drugs 2020;80:775-96. [PMID: 32382948 DOI: 10.1007/s40265-020-01310-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
10 van Kessel SP, Bullock A, van Dijk G, El Aidy S. Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats. mSystems 2022;:e0119121. [PMID: 35076270 DOI: 10.1128/msystems.01191-21] [Reference Citation Analysis]
11 Brown EG, Goldman SM. Modulation of the Microbiome in Parkinson's Disease: Diet, Drug, Stool Transplant, and Beyond. Neurotherapeutics 2020;17:1406-17. [PMID: 33034846 DOI: 10.1007/s13311-020-00942-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]